---
title: "MeiraGTx surges in pre-market trading after reaching a gene therapy collaboration with Eli Lilly"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/265171096.md"
description: "Gene therapy company MeiraGTx Holdings saw its stock price rise 13.22% in pre-market trading on Monday, after the company announced a broad strategic collaboration with Eli Lilly to jointly develop and commercialize gene therapies for eye diseases. Under the agreement, the New York-based biotechnology company will grant Eli Lilly global exclusive rights to its AAV-AIPL1 gene therapy program to develop a treatment for a hereditary eye disease. This disease is Leber Congenital Amaurosis Type 4 (LCA4), caused by a defect in the aryl hydrocarbon interacting protein-like 1 (AIPL1) gene, which MeiraGTx has identified as one of the most severe hereditary retinal dystrophies. According to the agreement, the Indiana-based pharmaceutical giant will also gain rights to several other gene therapy technologies from MeiraGTx. In exchange, MeiraGTx will receive a $75 million upfront payment and will be eligible for over $400 million upon achieving certain milestones. Additionally, the company will qualify for tiered royalties from potential sales of the licensed products"
datetime: "2025-11-10T13:54:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265171096.md)
  - [en](https://longbridge.com/en/news/265171096.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265171096.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/265171096.md) | [English](https://longbridge.com/en/news/265171096.md)


# MeiraGTx surges in pre-market trading after reaching a gene therapy collaboration with Eli Lilly

According to Zhitong Finance APP, gene therapy company MeiraGTx Holdings (MGTX.US) saw its stock price rise 13.22% in pre-market trading on Monday, after the company announced a broad strategic collaboration with Eli Lilly (LLY.US) to jointly develop and commercialize gene therapies for eye diseases.

Under the agreement, the New York-based biotechnology company will grant Eli Lilly global exclusive rights to its AAV-AIPL1 gene therapy program to develop a treatment for a hereditary eye disease.

This disease is Leber Congenital Amaurosis Type 4 (LCA4), caused by a defect in the Arylhydrocarbon Interacting Protein Like 1 (AIPL1) gene, which MeiraGTx has identified as one of the most severe hereditary retinal disorders.

According to the agreement, the Indiana-based pharmaceutical giant will also gain rights to several other gene therapy technologies from MeiraGTx.

In exchange, MeiraGTx will receive a $75 million upfront payment and will receive over $400 million upon achieving certain milestones. Additionally, the company will be eligible to receive tiered royalties from potential sales of the licensed products

### 相關股票

- [MeiraGTx (MGTX.US)](https://longbridge.com/zh-HK/quote/MGTX.US.md)
- [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md)

## 相關資訊與研究

- [MeiraGTx Highlights Late-Stage Gene Therapy Pipeline at RBC Ophthalmology Conference](https://longbridge.com/zh-HK/news/280608481.md)
- [Eli Lilly: Foundayo will be available with prescriptions accepted immediately and shipping from April 6](https://longbridge.com/zh-HK/news/281395595.md)
- [Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances](https://longbridge.com/zh-HK/news/281090118.md)
- [InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly](https://longbridge.com/zh-HK/news/280909399.md)
- [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/zh-HK/news/281171668.md)